The compelling Phase 2 data positions divesiran as a potential best-in-class therapy for PV, a large underserved market (~150K US patients). Watch for Phase 3 start in 1H 2027 and potential partnership or licensing interest. The stock is likely to see a strong positive reaction; monitor the conference call for further details on regulatory path and commercial strategy.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $15.43entry
- T+1 · 3mo ago −4.60%α −4.28% · $14.72
- T+5 · 3mo ago −7.00%α −6.95% · $14.35
- T+20 · 2mo ago −11.28%α −10.36% · $13.69
- T+60 · 14d ago +28.19%α +30.61% · $19.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). The primary endpoint was met with a significantly higher proportion of clinical responders (88% vs 19% placebo; p<0.0001), and both Q6W and Q12W dosing showed strong efficacy (93.8% and 81.3% response rates, respectively). The company plans to initiate a Phase 3 trial in 1H 2027, supporting divesiran's potential as a best-in-class siRNA therapy for PV.
Key Facts
- Primary endpoint met: 88% clinical responders for divesiran vs 19% placebo (p<0.0001), placebo-adjusted response rate 69%.
- Dose groups: 93.8% response at Q6W and 81.3% at Q12W.
- Key secondary endpoint: mean phlebotomies reduced to 0.2 (divesiran) vs 2.1 (placebo) during weeks 0-36 (p<0.0001).
- Safety well-tolerated with no new findings; injection site reactions infrequent and self-limiting.
- Phase 3 trial evaluating divesiran Q12W vs placebo expected to initiate in first half of 2027.
Financial Impact
No financial data reported; clinical-stage biotech with no revenue. Positive data could significantly increase probability of success and potential partnership value.
Risk Factors
- Phase 3 trial failure or safety issues could derail development.
- Regulatory hurdles for siRNA therapy in PV.
- Competition from existing therapies (JAK inhibitors, interferon) and other pipeline candidates.
- Need for additional capital to fund Phase 3 and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341293 |
| Document: d12947dex991.htm | 0001193125-26-341293 |
| Document: d12947dex992.htm | 0001193125-26-341293 |
| Document: 0001193125-26-341293-index-headers.html | 0001193125-26-341293 |
| Document: 0001193125-26-341293-index.html | 0001193125-26-341293 |
| Document: 0001193125-26-341293.txt | 0001193125-26-341293 |
Track record
15 reports on SLN
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +7.95% at T+20 after the Aug 10, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers